Your browser doesn't support javascript.
loading
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.
Gallelli, Giuseppe; Di Mizio, Giulio; Palleria, Caterina; Siniscalchi, Antonio; Rubino, Paolo; Muraca, Lucia; Cione, Erika; Salerno, Monica; De Sarro, Giovambattista; Gallelli, Luca.
Afiliação
  • Gallelli G; Department of Vascular Surgery, Pugliese Ciaccio Hospital, 88100 Catanzaro, Italy.
  • Di Mizio G; Forensic Medicine, Department of Law, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
  • Palleria C; Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, 88100 Catanzaro, Italy.
  • Siniscalchi A; Department of Neurology and Stroke Unit, Annunziata Hospital of Cosenza, 87100 Cosenza, Italy.
  • Rubino P; Department of Vascular Surgery, Pugliese Ciaccio Hospital, 88100 Catanzaro, Italy.
  • Muraca L; Department of General Medicine, ASP 7 Catanzaro, 88100 Catanzaro, Italy.
  • Cione E; Department of Pharmacy Helath and Nutritional Sciences, Department of Excellence 2018-2022, University of Calabria, 87036 Rende, Italy.
  • Salerno M; Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95041 Catania, Italy.
  • De Sarro G; Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, 88100 Catanzaro, Italy.
  • Gallelli L; Department of Health Science, School of Medicine, Clinical Pharmacology Research Center FAS@UMG, University of Catanzaro, 88100 Catanzaro, Italy.
Nutrients ; 13(6)2021 Jun 13.
Article em En | MEDLINE | ID: mdl-34199189
ABSTRACT
Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1 patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2 patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3 patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22-92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients' clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Venosa / Subtilisinas / Trombose Venosa / Fibrinolíticos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Nutrients Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Venosa / Subtilisinas / Trombose Venosa / Fibrinolíticos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Nutrients Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália